- Zacks Small Cap Research•last month
MediciNova (MNOV) is developing MN-166 (ibudilast) for the treatment of primary and secondary progressive multiple sclerosis (PPMS and SPMS), amyotrophic lateral sclerosis (ALS), methamphetamine (MA) addiction, opioid dependence, and alcohol dependence. The drug is currently being tested in four separate clinical trials in the aforementioned indications with two trials recently completed in alcohol dependence and opioid dependence. MN-166 is an anti-inflammatory drug that has been used for over 20 years in Japan to treat asthma (Rolan et al., 2009) and post-stroke dizziness.
- GlobeNewswire•last monthMediciNova Receives Notice of Allowance for New Patent Covering MN-001 and MN-002 for the Treatment of Fibrosis
LA JOLLA, Calif., July 24, 2016-- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market and the JASDAQ Market of the Tokyo Stock Exchange, today announced that it has received ...
- GlobeNewswire•2 months agoMediciNova Announces Initiation of Interim Efficacy Analysis in Phase 2b Trial of MN-166 (ibudilast) in Progressive MS
LA JOLLA, Calif., July 13, 2016-- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market and the JASDAQ Market of the Tokyo Stock Exchange, today announced that 50% of patients ...
MediciNova Inc. (MNOV)
NasdaqGM - NasdaqGM Real Time Price. Currency in USD
|Bid||5.19 x 100|
|Day's Range||5.88 - 6.05|
|52wk Range||2.62 - 10.16|
|1y Target Est||N/A|
Trade prices are not sourced from all markets
|P/E Ratio (ttm)||-16.14|
|Avg Vol (3m)||143,778|
|Dividend & Yield||N/A (N/A)|